S
Songsak Kiatchoosakun
Researcher at Khon Kaen University
Publications - 44
Citations - 1264
Songsak Kiatchoosakun is an academic researcher from Khon Kaen University. The author has contributed to research in topics: Percutaneous coronary intervention & Conventional PCI. The author has an hindex of 12, co-authored 41 publications receiving 1101 citations. Previous affiliations of Songsak Kiatchoosakun include University Hospitals of Cleveland.
Papers
More filters
Journal ArticleDOI
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Milton Packer,John J.V. McMurray,Akshay S. Desai,Jianjian Gong,Martin Lefkowitz,Adel R. Rizkala,Jean L. Rouleau,Victor Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile,Karl Andersen,Juan Luis Arango,J. Malcolm O. Arnold,Jan Belohlavek,Michael Böhm,Sergey Boytsov,Lesley J. Burgess,Walter Cabrera,Carlos Calvo,Chen Huan Chen,Andrej Dukát,Yan Carlos Duarte,Andrejs Erglis,Michael Fu,Efrain Gomez,Angel Gonzàlez-Medina,Albert A. Hagège,Jun Huang,Tzventana Katova,Songsak Kiatchoosakun,Kee-Sik Kim,Ömer Kozan,Edmundo Alfredo Bayram Llamas,Felipe Martinez,Béla Merkely,Ivan Mendoza,Arend Mosterd,Marta Negrusz-Kawecka,Keijo Peuhkurinen,Felix José Alvarez Ramires,Jens Refsgaard,Arvo Rosenthal,Michele Senni,Antonio S. Sibulo,José Silva-Cardoso,Iain B. Squire,Randall C. Starling,John R. Teerlink,Johan Vanhaecke,Dragos Vinereanu,Raymond Ching-Chiew Wong +51 more
TL;DR: Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotens in-converting enzyme inhibition.
Journal ArticleDOI
Naturally occurring variation in cardiovascular traits among inbred mouse strains.
Brian D. Hoit,Songsak Kiatchoosakun,Joseph Restivo,Darryl L. Kirkpatrick,Keith Olszens,Haifeng Shao,Yoh Han Pao,Joseph H. Nadeau +7 more
TL;DR: The data suggest that relative to A/J, B6 mice have a phenotype characteristic of the "athlete's heart," that is, eccentric, physiologic hypertrophy, slower heart rates, and increased exercise endurance.
Journal ArticleDOI
Geographic variations in the PARADIGM-HF heart failure trial.
Søren Lund Kristensen,Felipe Martinez,Pardeep S. Jhund,Juan Luis Arango,Jan Bĕlohlávek,Sergey Boytsov,Walter Cabrera,Efrain Gomez,Albert Hagège,Jun Huang,Songsak Kiatchoosakun,Kee-Sik Kim,Ivan Mendoza,Michele Senni,Iain B. Squire,Dragos Vinereanu,Raymond Chiew-Chiew Wong,Jianjian Gong,Martin Lefkowitz,Adel R. Rizkala,Jean L. Rouleau,Victor Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile,Milton Packer,John J.V. McMurray +26 more
TL;DR: There were many regional differences in PARADIGM-HF, including in age, symptoms, comorbidity, background therapy, and event-rates, although these did not modify the benefit of sacubitril/valsartan.
Journal ArticleDOI
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
John J.V. McMurray,Milton Packer,Akshay S. Desai,Jianjian Gong,Nicola Greenlaw,Martin Lefkowitz,Adel R. Rizkala,Victor Shi,Jean L. Rouleau,Scott D. Solomon,Karl Swedberg,Michael R. Zile,Karl Andersen,Juan Luis Arango,Malcolm Arnold,Jan Bělohlávek,Michael Böhm,Sergey Boytsov,Lesley J. Burgess,Walter Cabrera,Chen Huan Chen,Andrejs Erglis,Michael Fu,Efrain Gomez,Ángel Fernández González,Albert Hagège,Tzvetana Katova,Songsak Kiatchoosakun,Kee Sik Kim,Edmundo Bayram,Felipe Martinez,Béla Merkely,Ivan Mendoza,Arend Mosterd,Marta Negrusz-Kawecka,Keijo Peuhkurinen,Felix José Alvarez Ramires,Jens Refsgaard,Michele Senni,Antonio S. Sibulo,José Silva-Cardoso,Iain B. Squire,Randall C. Starling,Dragos Vinereanu,John R. Teerlink,Raymond Wong +45 more
TL;DR: In this paper, the angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF, and the results showed that the strategy of combined renin receptor blockade and neprilysin inhibition led to striking reductions in cardiovascular and all-cause mortality, as well as heart failure hospitalization.
Journal ArticleDOI
Blood Transfusion After Percutaneous Coronary Intervention and Risk of Subsequent Adverse Outcomes: A Systematic Review and Meta-Analysis.
Chun Shing Kwok,Matthew W. Sherwood,Sarah M. Watson,Samina B. Nasir,Matthew Sperrin,James Nolan,Tim Kinnaird,Songsak Kiatchoosakun,Peter Ludman,Mark A. de Belder,Sunil V. Rao,Mamas A. Mamas +11 more
TL;DR: Clinicians should minimize the risk for periprocedural transfusion by using available bleeding-avoidance strategies and avoiding liberal transfusion practices.